Skip to content

Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01352923
Enrollment
0
Registered
2011-05-12
Start date
2011-05-31
Completion date
2012-05-31
Last updated
2024-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet Function

Keywords

PEAR1 gene, PEAR 1 gene

Brief summary

In this study PEAR1 polymorphisms effects will be analyze in blood platelets to determine how PEAR1 regulates platelet activation.

Detailed description

Several large-scale studies have confirmed the long held notion that platelet responses to different agonists are highly variable, within well defined populations of healthy donors. Single nucleotide polymorphisms in genes encoding platelet proteins can explain the wide range of responses to standard platelet agonists. Yet, numerous SNPs point towards proteins with previously unknown function in platelets, wich modulate the complex network of signaling events that regulate platelet function and further augment variability. PEAR1 is mainly expressed in platelets and endothelial cells. A few studies have linked SNPs in PEAR1 with decreased or increased platelet responses to various agonists. However, hitherto, no direct functional studies have been carried out to determine whether and how PEAR1 modulate intracellular signaling pathways relevant for platelet function.

Interventions

OTHERblood test

preparation of blood platelets

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy voluntary donors

Exclusion criteria

* none

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026